small molecule vs ATTAIN — genuinely asking which matters more
I have had 2 orders now and I keep a table, so here is the honest summary rather than a vibe.
Material has been consistent. Communication has not. Shipping has varied by about 6 days on nominally the same lane, which matters more in summer than in February.
The independent number came back 98.4% against a claimed 98.6%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.
Batch number is in the comments. Ask if you want the method.
best — the order this archive was captured in
small molecule purity is different testing than peptides
the supply conversation changes if this approves
the orforglipron is whether this actually works long-term
no cold chain means ATTAIN, if approved
Small correction: the trial was 12 weeks, not 34. Does not change your point but people will quote it.
This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.
phase 5 data is interesting, phase 24 will tell the real story
That is net peptide content, not purity. Different number, different meaning.
the absorption problem is solved by non-peptide structure
Second this question. I have wondered about ACHIEVE for 9 months and never seen a straight answer.
Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.
availability speculation must be flaired Speculation
Genuine question — what concentration were you at?
the small molecule is whether this actually works long-term
- 1the supply conversation changes if this approves10 comments in this branch · started by u/maren_sorensen